← All indications
Scleroderma, Diffuse
A rapid onset form of SYSTEMIC SCLERODERMA with progressive widespread SKIN thickening over the arms, the legs and the trunk, resulting in stiffness and disability.
Drugs by status
Phase 3 trials (10)
Phase 2 trials (26)
Phase 1 trials (10)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (20)
- Actelion
- United Therapeutics
- Gilead Sciences
- Eli Lilly
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- Instituto Mexicano del Seguro Social
- Johns Hopkins University
- Postgraduate Institute of Medical Education and Research
- University of Groningen
- University of Michigan
- University of Rochester
- Tel Aviv University
- University of California, Los Angeles
- Government of Mexico
- A.O. Ospedale Maggiore di Lodi
- Sintesi Research Srl
- Mastelli srl, via Bussana Vecchia, Sanremo, Italy
- Federal University of Sao Paulo
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (53)
- Zenyaku Kogyo Co., Ltd.
- Roche
- Allergan
- Corbus Pharmaceuticals Inc.
- Kyowa Hakko Kirin
- Shanghai Genomics, Inc.
- Boehringer Ingelheim
- MediQuest Therapeutics
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Center for Research Resources (NCRR)
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Arizona
- University of Pittsburgh
- Alexandria University
- Boston University
- University of London
- Cornell University
- Duke University
- Georgetown University
- University of Washington
- Kanazawa University
- Medical College of Wisconsin
- Northwestern University
- Ochsner Health System
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
- Stanford University
- University of East Anglia
- University of Kentucky
- University of Medicine and Dentistry of New Jersey
- University of Toronto
- +23 more
Organization Involved with Phase 2 Indications (82)
- CSL Behring
- Regeneron
- Human Genome Sciences
- Kadmon
- Active Biotech AB
- Seattle Genetics
- Cambridge Antibody Technology
- Celgene
- Bristol-Myers Squibb
- Galapagos NV
- Schering-Plough
- Merck Serono
- Genentech
- Merck KGaA
- Genzyme
- Pfizer
- Sanofi
- Novartis
- Bayer
- Cumberland Pharmaceuticals
- Daval International Limited
- Digna Biotech S.L.
- Fibrocell Technologies, Inc.
- GlaxoSmithKline
- ISDIN
- Inventiva Pharma
- ZonMw: The Netherlands Organisation for Health Research and Development
- Medical Research Council
- National Cancer Institute (NCI)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- +52 more
Organization Involved with Phase 1 Indications (18)
- Amgen
- MedImmune
- Biogen
- Horizon Therapeutics, LLC
- Forbius
- Baylor University
- New York Medical College
- New York University
- Pontificia Universidad Catolica de Chile
- Radboud University
- University of South Carolina
- University of Athens
- Columbia University
- City of Hope National Medical Center
- Methodist Cancer Center, Houston, Texas
- Aspreva Pharmaceuticals
- Thai Rheumatism Association
- Viela Bio
Organization Involved with Other Experimental Indications (11)